On October 31, The U.S. Food and Drug Administration (FDA) approved Amgen’s WEZLANA (ustekinumab-auub) as a biosimilar to and interchangeable with Janssen’s STELARA (ustekinumab). WEZLANA has become the first product to be granted approval as a biosimilar to STELARA. This news has created significant ripples in the pharmaceutical industry, given that biosimilars are expected to play a consequential role in the sustainability of healthcare provision.
The approval of Amgen’s WEZLANA is an integral part of evolving pharmaceutical strategies that prioritize the development of biosimilar and interchangeable biologic drugs. As biologic drugs have increasingly been used to cure or manage burdensome or chronic diseases, products such as WEZLANA could be pivotal in meeting public health objectives while alleviating the financial burden associated with long-term drug use.
It is important to note, however, that being a biosimilar does not mean that WEZLANA and STELARA are identical drugs. They are closely comparable in terms of safety, potency, and efficacy. The term interchangeable implies that the new biosimilar may be alternated with the reference product without the intervention of the prescriber. Furthermore, post-marketing surveillance will be critical in understanding the full impact of the interchangeability of these products, ensuring safety and effectiveness in a real-world context.
This development marks a significant step forward in the pharmaceutical and healthcare industry. As we continue to observe the space, it will be interesting to gauge the manner in which the development, approval, and marketing of biosimilars and interchangeable biologics evolve to facilitate care in indications that previously had limited therapeutic options.
For a detailed insight into the FDA approval, consult the report on JD Supra.